ライフサイエンスコーパス: 50% lethal dose

1 n otherwise lethal challenge with T3D (100 x 50% lethal dose).

2 ith a lethal dose of ZEBOV (30,000 times the 50% lethal dose).

3 vaccinated mice from a live challenge (>300 50% lethal doses).

4 1 at doses up to 1,000-fold greater than the 50% lethal dose.

5 inst toxin doses of at least 10(4) times the 50% lethal dose.

6 not attenuated for virulence in an assay of 50% lethal dose.

7 intraperitoneal challenge as assessed by the 50% lethal dose.

8 ntracerebral inoculation of HSV-1 KOS at the 50% lethal dose.

9 d NO production that correlated with the LPS 50% lethal dose.

10 dicated by a > or = 400-fold increase in the 50% lethal dose.

11 60% of the animals to die at a dose of three 50% lethal doses.

12 zed mothers showed 100% protection against a 50% lethal dose (1 LD(50)) challenge and 50% protection

13 mice >24 months old were injected with 1 LD(50) (lethal dose 50) of influenza A virus.

14 (6) CFU of aerosolized Yersinia pestis CO92 (50% lethal dose, 6.8 x 10(4) CFU).

15 gainst intranasal challenge with 235,000 (10 50% lethal doses) Ames strain B. anthracis spores.

16 rulence for orally infected BALB/c mice in a 50% lethal dose analysis.

17 ate promoter (U(L)38) exhibited an increased 50% lethal dose and a 10-fold decrease in virus yields i

18 urface expression was correlated with higher 50% lethal dose and less corneal scarring in vivo.

19 iver, kidney and urine and 25-fold-decreased 50% lethal dose and milder histopathological injury in h

20 rease in neurovirulence as determined by the 50% lethal dose and survival distribution in suckling mi

21 al Y. pestis CO92 infection and have similar 50% lethal doses and kinetics of infection with respect

22 ent in the IL-6(-/-) mice (60-fold decreased 50% lethal dose) and colonized systemic tissues more rap

23 on of gK-myc in rabbit skin cells, increased 50% lethal dose, and decreased corneal scarring in ocula

24 challenge with approximately 1,000 times the 50% lethal dose ( approximately 1,000x LD(50)) of B. ant

25 In addition, virulence studies, using the 50% lethal dose assay, showed that the restoration of ca

26 ted strains were fully virulent in the mouse 50% lethal dose assay.

27 Virulence 50% lethal dose assays and serial sacrifice experiments

28 ti-IL-6-treated mice, showed greatly reduced 50% lethal doses compared to wild-type (WT) mice.

29 Data from 50% lethal dose determinations and the in vivo yields of

30 The 50% lethal doses differed among inbred strains of mice,

31 ided protection from lethal challenge (1,000 50% lethal doses) equal to that of the wild-type virus.

32 Y. enterocolitica infection were assessed in 50% lethal dose experiments.

33 g Psa) led to a 130,000-fold increase in the 50% lethal dose for mice relative to that of the KIM5 pa

34 etion in rat ileal loops was 200 ng, and the 50% lethal dose for mice was 27.5 ng when injected intra

35 However, the 50% lethal dose for pmE314 in adult NIH Swiss outbred mi

36 , at dosages as high as 500 times the normal 50% lethal dose for the wild-type parent.

37 segment, determining lethality with log(10) 50% lethal doses for each PTV genotype as follows (L/M/S

38 This was reflected in the estimated 50% lethal doses for the two strains (10(6) and 10(8) CF

39 condary lethal challenge of more than 10,000 50% lethal doses given 3 days later.

40 nts tested intragastrically, 12 mutants with 50% lethal doses greater than 1, 000 times that of the p

41 le of active immunization (mouse intravenous 50% lethal dose, > 10(7) bacteria), and stable at 4 degr

42 mutants showed a 1-to 3-log increase in the 50% lethal dose; however, the magnitude of its effect wa

43 y challenge with 1,000 mouse intraperitoneal 50% lethal doses (i.p. LD50) of BoNT/A.

44 strain OG1RF showed a considerably increased 50% lethal dose in a mouse peritonitis model, and, at hi

45 etaRS), showed delayed killing and a higher 50% lethal dose in a mouse peritonitis model.

46 mutants showed delayed killing and a higher 50% lethal dose in a mouse peritonitis model.

47 /kg body weight intravenously) increased the 50% lethal dose in mice by 100-fold after an intravenous

48 ail mutant exhibited a >3,000-fold-increased 50% lethal dose in mice.

49 sed pathogenicity as determined by increased 50% lethal doses, indicating that the proteins of the E3

50 Oral 50% lethal dose (LD(5)(0)) analyses showed that the NTS

51 ighly neurovirulent in 21 day-old mice, with 50% lethal dose (LD(5)(0)) values of 0.1 and 0.5 log(1)(

52 Dox + Val showed a 4-fold reduction in the 50% lethal dose (LD(50)) after 48 hours.

53 with the rovA mutant they are attenuated by 50% lethal dose (LD(50)) analysis and have altered kinet

54 s administered i.n. but actually reduced the 50% lethal dose (LD(50)) by 3 orders of magnitude when t

55 lly virulent phenotype as demonstrated using 50% lethal dose (LD(50)) experiments in mice.

56 vj mouse strains presented no differences in 50% lethal dose (LD(50)) following oral infection with Y

57 ntracerebral inoculation in BALB/c mice, the 50% lethal dose (LD(50)) for Myb34.5 was 2.7 x 10(7) PFU

58 The 50% lethal dose (LD(50)) for young B10.T(6R) mice was ap

59 Vero cells than Stx2a, but Stx2a has a lower 50% lethal dose (LD(50)) in mice.

60 ed by determination of the intracranial (IC) 50% lethal dose (LD(50)) in mice.

61 t loss and death in mice challenged with ten 50% lethal dose (LD(50)) inoculums of either H1N1, H3N2,

62 apB is significantly attenuated in mice; the 50% lethal dose (LD(50)) intranasally (i.n.) is >10,000-

63 For RJHM, the 50% lethal dose (LD(50)) is <10(1.3) in wild-type mice a

64 caused a lethal infection in the fly, with a 50% lethal dose (LD(50)) of 5 CFU.

65 in a dose-dependent manner with a calculated 50% lethal dose (LD(50)) of 680 PFU, whereas there were

66 or infection by the Ames strain, because the 50% lethal dose (LD(50)) of a PA-deficient (PA(-)) Ames

67 or recD do not affect the time course or the 50% lethal dose (LD(50)) of the infection.

68 n, following intranasal inoculation with 10x 50% lethal dose (LD(50)) of vaccinia virus strain IHD-J.

69 Administration of either the 50% lethal dose (LD(50)) or 10x LD(50) of Salmonella ent

70 had an approximately 90-fold increase in the 50% lethal dose (LD(50)) relative to the Yfe(+) Feo(+) p

71 ts displayed an approximately 24-fold-higher 50% lethal dose (LD(50)) than transport mutants.

72 casp-1(-/)- mice) had an oral S. typhimurium 50% lethal dose (LD(50)) that was 1,000-fold higher than

73 ttenuated 100-fold compared to the published 50% lethal dose (LD(50)) values for B. anthracis Ames af

74 rotected against challenge with 10 times the 50% lethal dose (LD(50)), and mice challenged with 1,000

75 dose which was 100,000-fold greater than the 50% lethal dose (LD(50)).

76 a monkeypox virus challenge of 65 times the 50% lethal dose (LD(50)).

77 burden and to a significant increase in the 50% lethal dose (LD) after subcutaneous infection.

78 tion were completely protected against a 10x 50% lethal dose (LD) challenge of Streptococcus pneumoni

79 solates of S. enteritidis, we determined the 50% lethal doses (LD(50)) in mice of isolates of two maj

80 ed from a dose equivalent to 1,000 to 10,000 50% lethal doses (LD(50)) of BoNT/A when given three or

81 odies and then challenged 48 h later with 10 50% lethal doses (LD(50)) of R. conorii.

82 given by the intraperitoneal route at as two 50% lethal doses (LD(50)).

83 pestis CO92 strain when it was given as five 50% lethal doses (LD(50)).

84 The 50% lethal doses (LD(50)s) for the Deltahcp2 through Del

85 Abs which together neutralized >40,000 mouse 50% lethal doses (LD(50)s) of A1 toxin but less than 500

86 The 50% lethal doses (LD(50)s) of the Deltacrp and araC P(BA

87 e against intraperitoneal challenge with 200 50% lethal doses (LD(50)s) of virulent Streptococcus pne

88 ulture infections, they exhibited lower oral 50% lethal doses (LD(50)s) than did the wild type in C57

89 s and found that for the majority tested the 50% lethal doses (LD(50)s) were >10(4.4) PFU.

90 CO92 Deltailp had a 55-fold increase in the 50% lethal dose ([LD(50)] 1.64 x 10(4) CFU) compared to

91 ikingly virulent in p47(phox)(-/-) mice (the 50% lethal dose [LD(50)] was <13 organisms).

92 taneous challenge with 8 x 10(5) CFU (80,000 50% lethal dose [LD(50)]) and intranasal challenge with

93 ltarfaH mutant strain is attenuated in mice (50% lethal dose [LD(50)], >10(8) CFU).

94 The 50% lethal dose (LD50) and mean time to death (MTD) of t

95 ensis LVS is lethal, with an intraperitoneal 50% lethal dose (LD50) approaching a single bacterium.

96 th the latter being unable to kill mice at a 50% lethal dose (LD50) equivalent to 6,800 LD50s of WT C

97 Our results suggest that the 50% lethal dose (LD50) falls within the range of 5 x 10(

98 We estimated that the 50% lethal dose (LD50) for cervidized transgenic mice wo

99 SPBNgamma has a 50% lethal dose (LD50) more than 100-fold greater than S

100 of the ompX mutant survived, compared to the 50% lethal dose (LD50) of 1.2 x 10(3) CFU for the wild-t

101 05) increased mortality, with an approximate 50% lethal dose (LD50) of 10(5) CFU, while an equivalent

102 We found that Stx2a had a 50% lethal dose (LD50) of 2.9 mug, but no morbidity occu

103 A) uniformly lethal to these animals, with a 50% lethal dose (LD50) of 5.3 x 10(-2) 50% tissue cultur

104 The 50% lethal dose (LD50) of alpha-factor for the calmoduli

105 traperitoneally (i.p.) with 10,000 times the 50% lethal dose (LD50) of gp-adapted EBOV, and naive gps

106 Moreover, the 50% lethal dose (LD50) of L/ST-n38 was comparable to tha

107 Specifically, we determined values of 50% lethal dose (LD50) of MERS-CoV for the 2 strains of

108 resulted in a threefold increase in the oral 50% lethal dose (LD50) of S. typhimurium for mice.

109 intratracheal challenge dose three times the 50% lethal dose (LD50) of strain J45.

110 J mutant in the blue gourami fish model: the 50% lethal dose (LD50) of the DeltaeseJ mutant is 2.34 t

111 d animals survived doses up to 400 times the 50% lethal dose (LD50) of the parental virus.

112 yphimurium ompD mutants was ascertained by a 50% lethal dose (LD50) study and by determining coloniza

113 By the injection route, LSU-E2 had a 50% lethal dose (LD50) that was greater than 5 logs10 hi

114 The 50% lethal dose (LD50) values of these strains are incre

115 398His substitution alone demonstrated log10 50% lethal dose (LD50) values too great to be measured.

116 monstrated no toxicity up to 500-fold of the 50% lethal dose (LD50) when it was injected systemically

117 or plcB resulted in small increases in mouse 50% lethal dose (LD50), deletions in both genes resulted

118 mice were challenged subcutaneously with 60 50% lethal doses (LD50) (1 LD50 = 1.9 CFU) of a virulent

119 n inoculum of 2 x 10(7) bacteria resulted in 50% lethal doses (LD50) in neonatal DBA/2 mice.

120 Lm/iglC, and subsequently challenged with 10 50% lethal doses (LD50) of aerosolized highly virulent F

121 nst lethal intranasal challenges with 1 or 5 50% lethal doses (LD50) of pathogenic vaccinia virus str

122 nic and protected BALB/c mice against 10,000 50% lethal doses (LD50) of S. Typhimurium or S. Enteriti

123 f pneumonic plague at a dose equivalent to 5 50% lethal doses (LD50) of wild-type (WT) CO92.

124 ized SCHU S4 at doses ranging from 50 to 500 50% lethal doses (LD50).

125 ations in glnA, ntrA, ntrB, or ntrC had i.p. 50% lethal doses (LD50s) of <10 bacteria, similar to the

126 hen Swiss-Webster mice, challenged with five 50% lethal doses (LD50s) of anthrax spores, were given a

127 he animals dying within 2 to 3 days with two 50% lethal doses (LD50s) of the WT bacterium.

128 thal intraperitoneal spore challenge with 24 50% lethal doses [LD50s] of B. anthracis Sterne and agai

129 mice who were aerosolized with 10(4) CFU (10 50% lethal doses [LD50s]).

130 eltarpoE mutant was highly attenuated with a 50% lethal dose more than 3 logs higher than that for th

131 e (YF-Vax) caused lethal encephalitis with a 50% lethal dose of 1.67 log(10) PFU.

132 brafish developed a lethal infection, with a 50% lethal dose of 10(3) CFU, and died within 2 to 3 day

133 Whereas wild-type VV had a 50% lethal dose of approximately 10(4) PFU after intrana

134 led an approximately twofold decrease in the 50% lethal dose of B. anthracis spores administered in t

135 hallenge ( approximately 60 to 450 times the 50% lethal dose of Bacillus anthracis Ames).

136 aspartate, previously shown to increase the 50% lethal dose of beta-toxin for mice nearly 13-fold, s

137 ate the relative degree of attenuation), the 50% lethal dose of CVD 915 (7.7 x 10(7) CFU) was signifi

138 test this, we infected BALB/c mice with 0.1 50% lethal dose of DeltaactA or virulent L. monocytogene

139 The 50% lethal dose of exoU-expressing strains was significa

140 There was a sixfold higher 50% lethal dose of HSV-1 in WT than IL-6 KO mice (1.7 x

141 The 50% lethal dose of Listeria was 10-fold lower for CapG(-

142 tigen-polyhistidine fusion peptide (Vh), the 50% lethal dose of purified lipopolysaccharide (LPS) in

143 The estimated 50% lethal dose of SH2099 was four times higher than tha

144 ant to protect A/J mice against 10 times the 50% lethal dose of Sterne strain spores introduced subcu

145 The 50% lethal dose of the Delta sod15 Delta sodA1 strain wa

146 significant sensitivity to UV light, and the 50% lethal dose of the mutant strain in a mouse intraper

147 ved an intranasal challenge with 5 times the 50% lethal dose of the pathogenic WR strain of vaccinia

148 challenge with approximately 10(4) times the 50% lethal dose of the wild-type SL1344 strain.

149 Nevertheless, the 72-h 50% lethal dose of the wild-type strain was 30-fold grea

150 The 50% lethal dose of these mutants in mice was 1.0 x 10(8)

151 intraperitoneal challenge with 50 times the 50% lethal dose of virulent S. pneumoniae WU2.

152 accinated mucosally were protected against a 50% lethal dose of wild-type SEB given i.p. or mucosally

153 rum elicited to nine-repeat alpha C protein (50% lethal doses of 1.6 x 10(3) and 1.8 x 10(5), respect

154 fully protected against a target dose of 200 50% lethal doses of aerosolized B. anthracis.

155 intraperitoneal challenge with 100 or 1,000 50% lethal doses of B. anthracis strain STI.

156 st that toxin activation may explain the low 50% lethal doses of B2F1 and H414-36/89 in streptomycin-

157 ee mAbs (oligoclonal Ab) neutralized 450,000 50% lethal doses of BoNT/A, a potency 90 times greater t

158 The aerosol 50% lethal doses of Burkholderia pseudomallei strain 102

159 against intravenous challenge with over 170 50% lethal doses of capsular type 3 strain WU2.

160 When challenged with 240 50% lethal doses of DENV2, mice given a single inoculati

161 oNT HCRs and neutralized challenge by 10,000 50% lethal doses of each of the seven BoNT serotypes.

162 flagellin produced by the strains; (ii) the 50% lethal doses of fliA mutant and wild-type strains of

163 ected the mice from in vivo challenge with 3 50% lethal doses of LeTx.

164 n of suckling mice against challenge with 25 50% lethal doses of mouse neurovirulent DENV-4 strain H2

165 ive against lethal aerosol challenge with 15 50% lethal doses of SEB.

166 In an acute pneumonia model, the 50% lethal doses of the galU mutants were higher than th

167 o mice subsequently challenged with 100 i.p. 50% lethal doses of the highly virulent TBEV.

168 subsequently challenged intranasally with 5 50% lethal doses of the parental wild-type.

169 hat for the wild-type spores even though the 50% lethal doses of the two strains were similar.

170 immunization, mice were challenged with 100 50% lethal doses of virulent S. pneumoniae WU2.

171 In mice, the 50% lethal doses of Y. pestis DeltahmuP'RSTUV mutants in

172 absence of YopM significantly increased the 50% lethal dose only in the intradermal model, suggestin

173 n O11 strain (9882-80) at 6 and 12 times the 50% lethal dose showed increased survival in mice that r

174 e levels in plasma and a significantly lower 50% lethal dose than those in LPS-treated control-fed an

175 more resistant to virus than CD1(-/-) mice (50% lethal dose titers: wild-type mice, 10 PFU; CD1(-/-)

176 n intraperitoneal challenge of up to 100,000 50% lethal dose units of BoNT/A.

177 ed with wild-type F. novicida (100 and 1,000 50% lethal doses) were highly protected (83% and 50% sur

178 usher, had an approximately 5-fold increased 50% lethal dose when administered orally to mice.

179 peritoneal route at a dose twice that of the 50% lethal dose, which within 2 to 3 days killed 100% of

180 infection (60%) than the WT bacterium at two 50% lethal doses, which resulted in 100% mortality withi

181 CT alone were challenged with 10(6) CFU (one 50% lethal dose) wild-type V. cholerae O1 El Tor strain